home / stock / pdsb / pdsb news


PDSB News and Press, PDS Biotechnology Corporation From 03/18/21

Stock Information

Company Name: PDS Biotechnology Corporation
Stock Symbol: PDSB
Market: NASDAQ
Website: pdsbiotech.com

Menu

PDSB PDSB Quote PDSB Short PDSB News PDSB Articles PDSB Message Board
Get PDSB Alerts

News, Short Squeeze, Breakout and More Instantly...

PDSB - PDS Biotechnology Corporation (PDSB) CEO Frank Bedu-Addo on Q4 2020 Results - Earnings Call Transcript

PDS Biotechnology Corporation (PDSB) Q4 2020 Earnings Conference Call March 18, 2021 08:00 A.M. ET Company Participants Deanne Randolph - IR Frank Bedu-Addo - CEO Lauren V. Wood - CMO Seth L. Van Voorhees - CFO Conference Call Participants Joseph Pantginis - H.C. Wainwright & Company Trev...

PDSB - PDS Biotechnology EPS misses by $0.06

PDS Biotechnology (PDSB): FY GAAP EPS of -$0.89 misses by $0.06.Cash balance as of December 31, 2020 was $28.8 million.Press Release For further details see: PDS Biotechnology EPS misses by $0.06

PDSB - PDS Biotech Reports Financial Results for the Year Ended December 31, 2020 and Provides Business Update

FLORHAM PARK, N.J., March 18, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune ® T-cell activating tech...

PDSB - PDS Biotechnology (PDSB) Investor Presentation - Slideshow

The following slide deck was published by PDS Biotechnology Corporation in conjunction with this event. For further details see: PDS Biotechnology (PDSB) Investor Presentation - Slideshow

PDSB - PDS Biotech Announces Presentation and Panel Participation at the Benzinga Biotech Small Cap Conference

Florham Park, New Jersey--(Newsfile Corp. - March 17, 2021) - PDS Biotechnology Corporation (NASDAQ: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company's proprietary Versamune® T-cell activating technology, ...

PDSB - Eli Lilly, Magnite leads the premarket losers' pack

Torchlight Energy Resources (TRCH) -15% on business combination timingRubius Therapeutics (RUBY) -14% on initial data for RTX-240 in solid tumorsEntera Bio (ENTX) -13%.Nova LifeStyle (NVFY) -12%.NLS Pharmaceutics (NLSP) -12%.Eli Lilly and Company (LLY) -7% after ...

PDSB - Ulta Beauty, Chargepoint Holdings leads the premarket losers' pack

Marker Therapeutics MRKR -24% after prices stock offering.Timber Pharmaceuticals (TMBR) -25%.Evoke Pharma EVOK -24% on Q4 earnings release.FinVolution (FINV) -15%.Poshmark POSH -15% on Q4 earnings release; after Q1 revenue guidance falls short.AMMO POWW ...

PDSB - VIR, ALTO, PHUN and CELH among midday movers

Gainers: Entera Bio (ENTX) +223%.Nova LifeStyle (NVFY) +85%.PDS Biotechnology (PDSB) +54%.Phunware (PHUN) +50%.Takung Art (TKAT) +41%.FinVolution (FINV) +36%.RYB Education (RYB) +34%.Vir Biotechnology (VIR) +34%.Siebert Financial (SIEB) +33%.Super League Gaming (SLGG) +27%.Lose...

PDSB - PDS Biotech shares surge after receiving $60M funding for COVID-19 vaccine trial in Brazil

PDS Biotechnology's (PDSB) COVID-19 vaccine consortium has received a commitment from the Secretary for Research and Scientific Training of the Ministry of Science, Technology and Innovation of Brazil ((MCTI)) to fund up to ~$60M to support the development and commercialization of Versamune-b...

PDSB - PDS Biotech Announces that its COVID-19 Vaccine Consortium Received a Commitment from The Ministry of Science, Technology and Innovation of Brazil (MCTI) to fund Clinical Development and Commercialization of a Versamune®-Based COVID-19 Vaccine with a

FLORHAM PARK, N.J., March 11, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on PDS Biotech’s proprietary Versamune ® T-cell activating tech...

Previous 10 Next 10